Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why DreamWorks Animation, Vertex Pharmaceuticals, and Karyopharm Therapeutics Tumbled Today

On Monday, stocks were generally little changed, as investors waited for greater clarity on the situation in Iraq and on the state of the global economy. Merger and acquisition activity continued to play an important role in the market, with high-profile combinations again revealing the incentives in international mergers designed to escape U.S. corporate taxation. Yet even though most major market benchmarks didn't make any big moves today, the news was much different at the individual-stock level. Among the worst performers today were DreamWorks Animation (NASDAQ: DWA  ) , Vertex Pharmaceuticals (NASDAQ: VRTX  ) , and Karyopharm Therapeutics (NASDAQ: KPTI  ) , each of which made substantial drops Monday.

Source: DreamWorks Animation.

DreamWorks Animation dropped 11% after its How to Train Your Dragon 2 sequel failed to make the splash that investors had hoped to see. With $50 million in weekend box-office revenue, the movie wasn't a complete disaster for DreamWorks. But as the stakes for high-profile successes increase, DreamWorks will have less margin for error. Moreover, the disappointment reveals the risks involved in assuming that sequels will be able to match or even approach the success of their original installments, especially as the need for long-lived franchises to justify initial expenditures seems to increase.

Vertex Pharmaceuticals declined almost 9% after a stock analyst discussed concerns about the company's VX-809 cystic fibrosis treatment and its combination with Vertex's Kalydeco drug. Early indications from the company's phase 3 trial of the drug combination appear to be less than promising, with minimal efficacy and certain complications making some question the long-term viability of the drug as a recommended treatment. With much of the upward momentum in its stock price now gone, Vertex really needs a success on the trial front in order to dispel these long-term concerns about its viability in the future.

Karyopharm Therapeutics fell 12.5% Monday, but it's important to put the day's drop into context after the stock nearly doubled on Friday. Last week's positive news came after the biotech company announced positive results from its phase-1 trial of multiple-myeloma treatment selinexor. Today, Karyopharm came out with good news on the veterinary front, with its verdinexor drug approved by the FDA's veterinary wing for use in a relatively small population of dogs suffering from canine lymphoma. Even with the good news, it'll be years before Karyopharm's full potential can be realized -- absent a buyout in what has become an increasingly popular arena for merger and acquisition activity.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. To that end, there is a product in development that will change how we treat a common chronic illness and also potentially revolutionize the entire health industry. Analysts are already licking their chops at the sales potential. To outsmart Wall Street and realize multibagger returns, you need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. Click here now.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2996496, ~/Articles/ArticleHandler.aspx, 9/1/2015 12:22:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 3 hours ago Sponsored by:
DOW 16,528.03 -114.98 -0.69%
S&P 500 1,972.18 -16.69 -0.84%
NASD 4,776.51 -51.82 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

8/31/2015 3:59 PM
DWA $19.94 Down -0.35 -1.72%
DreamWorks Animati… CAPS Rating: ***
KPTI $13.86 Down -0.28 -1.98%
Karyopharm Therape… CAPS Rating: ***
VRTX $127.52 Down -6.53 -4.87%
Vertex Pharmaceuti… CAPS Rating: ***